SCHEMBL255899

SCHEMBL255899

Cc1cc(Nc2nc(C3(c4ccc(F)cc4)CCC3)nc3ccccc23)n[nH]1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 7/20 0.58
AURKA O14965 9/20 0.57
AURKB Q96GD4 6/20 0.57
SRC P12931 5/20 0.57
GSK3B P49841 5/20 0.57
EIF2AK2 P19525 1/20 0.57
GSK3A P49840 1/20 0.57
JAK2 O60674 3/20 0.56
CYP3A4 P08684 3/20 0.56
CYP2C8 P10632 3/20 0.56
CYP2C9 P11712 3/20 0.56
JAK1 P23458 3/20 0.56
TYK2 P29597 3/20 0.56
CYP2C19 P33261 3/20 0.56
JAK3 P52333 3/20 0.56
ADORA3 P0DMS8 2/20 0.56
CYP1A2 P05177 1/20 0.56
NTRK3 Q16288 1/20 0.52
NTRK2 Q16620 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164975 0.91 NTRK1 (0.56) NTRK1AURKAAURKBSRCGSK3B
SCHEMBL12430786 0.90 AURKA (0.61) NTRK1AURKAAURKBSRCGSK3B
SCHEMBL15209205 0.88 NTRK1 (0.56) NTRK1AURKAAURKBSRCGSK3B
SCHEMBL10134600 0.88 NTRK1 (0.56) NTRK1AURKAAURKBSRCGSK3B
SCHEMBL255898 0.87 JAK2 (0.56) NTRK1AURKAAURKBSRCGSK3B
SCHEMBL15215658 0.87 JAK2 (0.56) NTRK1AURKAAURKBSRCGSK3B
SCHEMBL15208949 0.87 JAK2 (0.56) NTRK1AURKAAURKBSRCGSK3B
SCHEMBL174822 0.83 NTRK1 (0.57) NTRK1AURKAAURKBSRCGSK3B
SCHEMBL15209234 0.82 NTRK1 (0.54) NTRK1AURKAAURKBSRCGSK3B
SCHEMBL176176 0.82 NTRK1 (0.54) NTRK1AURKAAURKBSRCGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012030910-A1 2-CYCLOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed